Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
Open Access
- 8 December 2020
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (1) , 69-80
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 45 references indexed in Scilit:
- Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension studyInternational Journal of Hematology, 2013
- Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)British Journal of Haematology, 2012
- ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused UpdateJACC, 2012
- Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopeniaMediterranean Journal of Hematology and Infectious Diseases, 2012
- Total Remission of Severe Immune Thrombocytopenia after Short Term Treatment with RomiplostimHematology Reports, 2011
- Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic ReviewPLOS ONE, 2011
- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAmerican Journal of Hematology, 2010
- The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature reviewEuropean Journal of Haematology, 2009
- RomiplostimDrugs, 2009
- EltrombopagDrugs, 2009